Kenya Cancer Induced Bone Diseases Therapeutics Market

Kenya Cancer Induced Bone Diseases Therapeutics Market


$ 3999

Kenya Cancer Induced Bone Diseases Therapeutics Market valued at $1 Mn in 2022, projected to reach $2 Mn by 2030 with a 6.9% CAGR. The key drivers of this industry include the rising incidence of cancer, the demographic shift to an aging population, and supportive government initiatives. The industry is primarily dominated by players such as Avenue Healthcare, AstraZeneca, Merck, Eli Lilly, Johnson & Johnson, Amgen, and Novartis among others.

ID: IN10KEPH440 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Riddhi Solanki

Buy Now

Kenya Cancer Induced Bone Diseases Therapeutics Market Analysis

Kenya Cancer Induced Bone Diseases Therapeutics Market valued at $1 Mn in 2022, projected to reach $2 Mn by 2030 with a 6.9% CAGR.

Cancer-induced bone disease pertains to a condition that arises either due to the impact of cancer on the bones or as a consequence of treatments administered to address the primary condition, leading to bone loss and fractures. The main symptom typically involves pain in the bones and joints, accompanied by potential indicators such as swelling, stiffness, or tenderness in the affected bone, challenges with movement, unexplained weight loss, a fractured bone, loss of sensation in the affected limb, and fatigue. Presently, treatment options for cancer-related bone disease include the use of bone-modifying agents like bisphosphonates and denosumab, recognized for their efficacy in preventing and delaying the emergence of issues related to cancer-induced bone problems. Other treatment modalities encompass surgery, chemotherapy, radiation therapy, targeted therapy, and various drug therapies. Major companies actively involved in the development and promotion of therapeutics for bone diseases include Amgen, Merck & Co., Roche, Novartis, Eli Lilly and Company, and Bayer AG.

Cancer presents a substantial public health challenge in Kenya, with prevalent types including breast, lung, prostate, and others, leading to the occurrence of bone metastases. The market is driven by factors such as the rising incidence of cancer, shifting demographic trends and supportive government initiatives in the therapeutics industry However, conditions such as limited spending capacity, health system challenges, and limited coverage of treatment limit the growth and potential of the market.

Kenya cancer induced bone diseases therapeutics market

Market Dynamics

Market Growth Drivers

Increasing incidence of cancer: Cancer poses a significant public health challenge in Kenya, marked by a consistent increase in both incidence and mortality rates. Kenya experiences more than 45,000 new cancer cases diagnosed annually. The growing burden of breast cancer with an estimated prevalence of 25%, lung cancer affecting around 7% population, and prostate cancer having an incidence of about 11% implies an increasing number of individuals at risk of developing cancer-induced bone diseases, driving the demand for therapeutic interventions.

Demographic shift: Kenya's population is undergoing an aging trend, with the proportion of individuals aged 60 and above projected to reach 10% by 2050. This demographic, more susceptible to cancer and bone-related complications like osteoporosis, may further intensify the challenges associated with cancer-induced bone diseases. The shifting demographics will lead to a larger patient pool in need of treatment for bone diseases linked to cancer.

Supportive government initiatives: The Kenyan government is progressively acknowledging the challenges posed by cancer and bone diseases, and is taking steps to enhance healthcare access and treatment. This involves directing increased resources toward cancer treatment centers, investing in research and development, and conducting awareness campaigns. These measures are anticipated to foster a conducive environment for the market of therapeutics for cancer-induced bone diseases.

Market Restraints

Limited spending capacity: The low GDP per capita in Kenya results in restricted disposable income for a majority of the population, posing a considerable obstacle to affording costly cancer treatments like monoclonal antibodies, including therapeutics for bone diseases

Health system challenges: Kenya struggles with a severe shortage of oncologists, radiologists, and other specialists who possess the expertise to diagnose and address cancer-induced bone diseases. This scarcity restricts access to specialized care and impedes the effective delivery of treatments. Additionally, the country lacks an adequate network of well-equipped healthcare facilities featuring dedicated oncology units and advanced diagnostic tools. Moreover, shortages and interruptions in the supply chain frequently impede access to crucial cancer medications and therapeutics for bone diseases, compromising the continuity and effectiveness of treatment.

Limited coverage: A considerable segment of the Kenyan population is without health insurance, requiring them to bear the entire expense of medical treatment. This presents a notable financial obstacle, particularly for intricate and costly therapies. Despite the Kenyan government allocating funds for healthcare, the allocated amount for cancer care and specialized treatments such as bone disease therapeutics is deemed inadequate.

Healthcare Policies and Regulatory Landscape

In Kenya, the regulatory authority overseeing pharmaceuticals, drugs, and other medical products is the Pharmacy and Poisons Board (PPB). The PPB is responsible for ensuring the safety, efficacy, and quality of pharmaceuticals and medical products in the country. It operates under the Pharmacy and Poisons Act and plays a crucial role in the licensing, registration, and monitoring of pharmaceutical products to safeguard public health.

Obtaining a license for pharmaceuticals and medical products in Kenya involves a comprehensive process overseen by the PPB. Applicants are required to submit detailed documentation, including information on the product's composition, manufacturing process, quality control measures, and evidence of compliance with Good Manufacturing Practices (GMP).

For new entrants in the pharmaceutical industry in Kenya, the regulatory environment presents both challenges and opportunities. While the stringent regulatory requirements ensure a high standard of quality and safety for pharmaceutical products, they may pose entry barriers for new companies due to the rigorous evaluation processes and compliance standards. However, the demand for healthcare products and services in Kenya presents an attractive market for potential entrants.

Competitive Landscape

Key Players

  • Roche
  • Amgen
  • Novartis
  • Eli Lilly
  • Pfizer
  • Avenue Healthcare
  • Bristol Myers Squibb
  • AstraZeneca
  • Merck& Co
  • Johnson & Johnson

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Kenya Cancer Induced Bone Diseases Therapeutics Market Segmentation

By Cancer Type

  • Breast cancer
  • Prostate cancer
  • Lung cancer
  • Others

By Treatment Type

  • Bisphosphonates
  • Denosumab
  • Radiation Therapy
  • Pain Management Medications
  • Surgical Intervention
  • Targeted Therapy

By Distribution channel

  • Hospitals
  • Pharmacies
  • Oncology clinics
  • Others

By Stage of Treatment

  • Early stage CIBD
  • Advanced stage CIBD

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 23 April 2024
Updated by: Bhanu Pratap Singh

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up